Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurjpc/zwad014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort.
Clin Exp Med
January 2025
Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.
The diagnostic criteria for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Metabolic Associated Steatotic Liver Disease (MASLD) aim to refine the classification of fatty liver diseases previously grouped under Non-Alcoholic Fatty Liver Disease (NAFLD). This study evaluates the applicability of the MAFLD and MASLD frameworks in NAFLD patients, exploring their clinical utility in identifying high-risk patients. A total of 369 NAFLD patients were assessed using MAFLD and MASLD diagnostic criteria.
View Article and Find Full Text PDFIntegrating Metabolomics Domain Knowledge with Explainable Machine Learning in Atherosclerotic Cardiovascular Disease Classification.
Int J Mol Sci
November 2024
Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, 3000 Leuven, Belgium.
Metabolomic data often present challenges due to high dimensionality, collinearity, and variability in metabolite concentrations. Machine learning (ML) application in metabolomic analyses is enabling the extraction of meaningful information from complex data. Bringing together domain-specific knowledge from metabolomics with explainable ML methods can refine the predictive performance and interpretability of models used in atherosclerosis research.
View Article and Find Full Text PDFASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individuals.
Circulation
December 2024
Department of Epidemiology (J.P., M.K., M.K.I., M.A.I., D.B., M.J.G.L.), Erasmus Medical Center-University Medical Center Rotterdam, The Netherlands.
Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk.
Am Heart J
December 2024
Cardiology Department, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address:
Background: Elevated lipoprotein(a) (Lp[a]) and apolipoprotein B (apoB) are individually associated with the risk of atherosclerotic cardiovascular disease (ASCVD). Moreover, previous basic research has implicated the potential interaction between apoB and Lp(a) in the atherogenic process. We aimed to determine whether apoB levels significantly modulate ASCVD risk associated with Lp(a) in a large community-based population without baseline cardiovascular disease.
View Article and Find Full Text PDFArticle Synopsis
- Lipoprotein(a) [Lp(a)] is recognized as a potential predictor for atherosclerotic cardiovascular disease (ASCVD), with a study involving 9944 Chinese patients revealing its association with increased cardiovascular event risk based on current risk stratification guidelines.
- Patients were categorized into very-high-risk (VHR) and non-VHR subgroups, with Lp(a) plasma levels influencing the prevalence of cardiovascular events (CVEs) observed over an average follow-up of 38.5 months.
- The results indicated that higher Lp(a) levels correlate with a significant increase in CVE risk, especially in the VHR subgroup, with adjusted hazard ratios showing a 2.18 times higher risk in the highest Lp
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!